Cyproheptadine hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for cyproheptadine hydrochloride and what is the scope of patent protection?
Cyproheptadine hydrochloride
is the generic ingredient in two branded drugs marketed by Actavis Mid Atlantic, Chartwell Molecular, Elysium, Halsey, Lyne, Morton Grove, Naska, Patrin, Pharm Assoc, Quagen, Tris Pharma Inc, Merck, Am Therap, Appco, Ascot, Beximco Pharms Usa, Chartwell Rx, Duramed Pharms Barr, Fosun Pharma, Heritage Pharma, Kenton, Kv Pharm, Md Pharm, Mountain, Mylan, Novast Labs, Pioneer Pharms, Pliva, Rising, Strides Pharma, Superpharm, Vitarine, Watson Labs, and Zydus Pharms, and is included in forty-one NDAs. Additional information is available in the individual branded drug profile pages.There are two drug master file entries for cyproheptadine hydrochloride. Twenty-three suppliers are listed for this compound.
Summary for cyproheptadine hydrochloride
US Patents: | 0 |
Tradenames: | 2 |
Applicants: | 34 |
NDAs: | 41 |
Drug Master File Entries: | 2 |
Finished Product Suppliers / Packagers: | 23 |
Raw Ingredient (Bulk) Api Vendors: | 92 |
Clinical Trials: | 27 |
Patent Applications: | 1,484 |
Formulation / Manufacturing: | see details |
What excipients (inactive ingredients) are in cyproheptadine hydrochloride? | cyproheptadine hydrochloride excipients list |
DailyMed Link: | cyproheptadine hydrochloride at DailyMed |
Recent Clinical Trials for cyproheptadine hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Bronx VA Medical Center | Phase 1 |
Laval University | Phase 2 |
Canadian Institutes of Health Research (CIHR) | Phase 2 |